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Abstract 
Background:The prevalence of HIV and HBV infections differs from place to place with few evidence on their risk 
factors. The aim of this study was to evaluate the seroprevalenceand risk factors of HIV, HBV in Ottou village, a 
communal area on the outskirts of Yaounde. Methods:A cross-sectional study was carried out from May to September 
2018 at “Sainte Monique”, a pediatric and gynecologic health centre. Associations between AIDS and HBV knowledge, 
demographics, behavior factors and blood transfusionand HIV and HBV infection were analyzed using a Chi-square and 
Odd ratio.Testswas performed using Epi info 7 withp<0.05, as significance.Results: Among 153 enrolled participants, the 
median age was 29 years old with interquartile range from 22 to 36 years. The prevalence of HIV, HBVand the co-
infection HIV/HBV was respectively 11.11% (17/153), 14.37% (22/153) and1.3% (2/153). We found that females were 
more infected by HIV than men (13.3% vs. 6.3%). Contrariwise, men were more infected by HBV (16.7% vs. 11.4%) 
however, the differences were not statistically significant, respectively (p= 0.31; p=0.37). Univariate analysis identified 
that multiple sexual partners (OR 3.35, 95% CI: 1.17-9.61, p=0.019) and the lack of awareness on HBV (OR 5.96, 95% 
CI: 1.97-18.07, p=0.0001)were associated risk factors to contracting HBV whereas having multiple sexual partners was 
the only identifiable risk factor for  HIV (OR 7.5,95% CI: 1.65-34.06, P=0.0064). Conclusions:Targeted, tailored, and 
comprehensive interventions are urgently needed to prevent the HIV and HBV infections in this locality. 
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Introduction 
Human Immunodeficiency Virus (HIV) and Hepatitis 
B Virus (HBV) infections represent particular health 
challenge in sub-Saharan Africa [1]. While HIV affects 
about 35.3 million people 2, WHO estimates that 
about 400 million people worldwide are infected by 
hepatitis B virus with high prevalence (8 to 15%) in 
Africa and Asia 1. Studies revealed that HBV 
infection may be present in the two-third of the 35.3 
million people living with HIV (PLHIV) in sub-
Saharan Africa [1]. Major clinical relevance of this co-
infection is that HBV-induced hepatitis in PLHIV leads 
to higher risks of liver-disease and associated-mortality 
than reported in HIV mono-infected patients [3, 4]. For 
HIV, it accelerates progression of HBV- or HCV-
associated chronic liver disease as well as a rapid 
progression to hepatocellular carcinoma (HCC) [5, 
6].HIV is an RNA virus that mainly targets the T-
lymphocytes bearing CD4 [7] while HBV is a 
hepatotropic virus that replicates predominantly in the 
hepatocytes [8]. Hepatitis B and HIV co-infection is 
common among patients because of shared routes and 
mechanisms of transmission [9, 10].  
In Cameroon, the new national AIDS control strategy 
is ‘‘test and treat” regardless of lymphocytes TCD4 
rate to achieve 90-90-90’’ target. Fulfilling such 
strategy implies an early diagnosis and immediate 
management of patients after being screened. In 2015, 
the prevalence of HIV/AIDS in Cameroon was on the 
decline (3.9%) while that of HBV was increasing 
(12.2%). The prevalence of those infections differs 
from place to place with few evidence on their risk 
factors. The importance of implementing appropriate 
prophylactic care and follow-up of patients mono 
infected by HBV and by HIV is fundamental. 
Furthermore, it is also important to identify the 
HIV/HBV co-infected patients ignorant of their status 
in the general population since HIV infected patients 
are systematically put on antiretroviral therapy without 
information on their HBV status. 
This study was undertaken to determine the prevalence 
of hepatitis B surface antigen (HBsAg), HIV, co-
infection of HIV/HBV and risk factors among patients 
in Ottou village, a peripheral area of Yaounde, the 
capital cityof Cameroon. 
 
 
Materials and Methods 
Participant’s enrolment 
A cross-sectional study was conducted from May to 
September 2018 at “Sainte Monique” pediatric and 
gynecologic health centre in Ottou. Overall 153 
participantswere enrolled by Snowball sampling. 
Participant recruitment was as follows: through the 
recommendation of Ministry of Public Health, some 
male volunteers who meet our requirements: i.e. over 
15 years old, and had sexual behavior, including oral 
and anal sex in the last 12 months. We selected the 
seeds according to the type of activity places, and 
encouraged the seeds to drive the same type 
companions to take part in our investigation. The 
companions also can drive his companions after his 
investigation. Ethical approval was obtained from the 
National Ethics Committee (n° 
2018/09/1105/CE/CNERSH/SP)of Cameroon. At the 
patient’s recruitment site, an information notice was 
administered to enroll the eligible patients, who then 
provided their informed consent prior to enrollment 
into the study. Parent's or guardian's informed concerns 
was also needed for minors’ participants (less than 21 
years of age). In addition, a personal interview with 
those minors was undertaken concerning some 
sensitives aspects such as sexuality. Confidentiality 
was secured by the use of identification codes 
attributed to each of the study participants. 
 
Demographic, clinical, sexual behavior features 
 
Data were collected on demographics, AIDS and HBV 
awareness, sexual behavior andblood transfusion in the 
standardized questionnaires that were administrated 
through face-to-face interviews by the trained 
physicians. Blood specimens were collected from 
participants and tested for diagnoses of HIV and 
HBV.Contact information including the mobile phone 
number of each participant was recorded. All 
participants were educated in the general information 
phase on HIV and HBV and trained on how to practice 
safe sex during pre-test and post-test counseling 
provided by this study. Each participant was given 
RDV to collect result.  
Laboratory testing 
A total of 5 mL of whole blood was collected from 
each study participant in a dry tube. Serum samples 
were collected and kept at -20ºC until assays of interest 
were run. HIV screening test was carried out by the 
HIV ½ rapid diagnostic tests (Determine™ HIV-½, 
Alere Medical Co., Japan) [11].Positives HIV tests 
were then confirmed by OraQuick® Rapid HIV-1/2 
Antibody Test (from Orasure Technologies, Inc. 
Bethlehem,PA 18015 USA) performedwith oral fluid, 
whole blood, serum or plasmaas recommended in 
Cameroon[12].The detection of HBsAg was performed 
using serological testing strategy as recommended by 
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WHO [13], the HBV One Step Rapid Assay DiaSpot® 
(Jawa Barat, Indonesia). This is a rapid 
chromatographic immunoassay test strip for visual 
reading andqualitative detection of HBsAg [14]. 
 
Statistical Analysis 
Questionnaires were double-entered and then checked 
for accuracy using Excel 2013 and analysed in Epi info 
7 software. Descriptive (mean, frequency and standard 
deviation) analyses were conducted to describe the 
demographic characteristics, AIDS and HBV 
awareness, behavior characteristics, prevalence of HIV 
and HBV. Categorical data were analyzed by Chi-
square test for possible association between variables. 
Odds ratios (OR) and their 95% confidence intervals 
(CI) were calculated in univariate analysis for possible 
presumptive variables. Variables with p= 0.05 were 
statistically significant. 
Results 
General characteristics of study population 
During the study period, 153 participants fulfilled the 
inclusion criteria. The mean age was 30.4 years ± 5.63 
years ranging from 14 to 68 years. Among them, 
68.6% (105/153) were females. Most of the study 
population was under 35 years old (77.1%) as shown in 
the figure 1. Forty four point six percent (71/153) of 
study participants were singles and 50.9% (78/153) 
were employees. For academic standards, 46.4% 
(71/153) had primary school level of education. Many 
of these participants declared to have never received an 
anti HBV vaccine % (139/153) and % (51/153) were 
not aware of hepatitis B. 
 
HIV and risk factors 
From this study, occupation of study participants was 
associated to HIV (p=0.03) with students and 
housewives mostly affected with 20% and 17.5% 
respectively. Women were more likely to be HIV 
positives than men (p=0.31). Subjects who seemed to 
be more infected by HIV were: patients of the age 
group 25 to 35 (16.7%), single (22.5%) and under-
educated groups (21.8%), table 1..  
Participants with multiple sexual partners were more 
affected by HIV 18.1% vs.1.3%, p=0.0064, OR=7.5. 
Subjects with irregular use of condom (12.5%), ano-
genital intercourses (25%) and surgery antecedent 
(14.3%) were likely to be HIV positive, table 1. 
Factors associated to HBV 
Like HIV, sociodemographic and behavorial factors 
were associated to HBV infection. Occupation of study 
participants was also associated to hepatitis B 
(p=0.011). Men were more likely to be HBV positive 
than women (OR:1.63, 95%CI: 0.64-4.13, p=0.3). 
Subjects of the age group 25 to35 (23.3%), single 
(16.9%) and under educated groups (28.1%) seemed 
more infected with HBV. Multiple sexual partners and 
the lack of awareness on HBV were risk factors 
(p=0.019 and p=0.0005 respectively), table 2.  
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Table 1: association between demographic characteristics, risk behavior and HIV 
 
Table 2. Behavioral factors associated to HBV 
Variables 
  
N=153 HIV Positive 
17 (11.1%) 
OR IC95% p-value 
 
Sex  
Female* 105 14(13.3%) 2.31 0.63-8.44 0.31 
Male 48 3(6.25%)    
Age (year)  
15-25 58 3(5,2%) NA  0.39 
25-35 60 10(16.7%)    
35-45 16 2(12.5%)    
45+ 19 2(10.5%)    
Use of condom  
Regular 10 0(00,0%) NA  0.79 
Irregular 113 14(12.5%)    




No 70 2(1.3%) 7.5 1.65-34.06 0.0064 
Yes*  83 15(18.1%)    
Types of sexual 
intercourses 
  NA   
Genital 114 12(10.5%)   0.79 
Oro-genital 31 3(9.6%)    
Ano-genital 8 2(25%)    
Blood transfusion      
No* 143 16 (11.1%) 1.13 0.13-9.54 0.69 
Yes 10 1(10%)    
OR=Odds Ratio, *=Reference level of  OR ;  IC95%= intervals of  Confidence   95%  





HBsAg Positive  
22 (14.4%) 
OR IC95%  p-value  
 
Multiple sexual partners  
No 70 5(7.1%) 3.35 1.17-9.61 0.019 
Yes*  83 17(20.5%)    
Use of condom  
Regular 10 1(10,0%) NA  0.99 
Irregular 113 16(14.2%)    
Never 30 5(16.7%)    
Statut  matrimonial  
Genital 114 18(15.7%) NA  0.12 
Oro-genital 31 1(3.2%)    
Ano-genital 8 3(37.5%)    
Awareness on HBV      
No* 51 12(23.5%) 5.96 1.97-18.07 0.0001 
Yes  102 5(4.9%)    
Anti HBV vaccination      
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This community-based survey showed HIV/HBV 
prevalence among youth in Cameroon. The survey 
identified wide distribution of HBV seroprevalence 
compared to HIV. This reflects the prevalence in 
Cameroon and it is known that HBV is 50 to 100 times 
more contagious than HIV 15. Indeed, HBV has been 
found in virtually all body secretions/excretions and 
unlike HIV, it can survives outside the body for at least 
7 days after which the virus can still cause infection 
16.  This prevalence of HBV in Ottou was closer to 
the national prevalence (12.2%) 17 than HIV (3.9%) 
[18). Due to the sample size probably, different results 
have been found by many authors in Cameroon with 
4.1% HBsAg vs 6% HIV 19 and 4.5% HBsAg vs 1% 
HIV 20.  HIV/HBsAg coinfection was 1.3% (2/153). 
In the same country Cameroon, contrary results have 
been already found21. Ameta-analysis prevalence 
study included 24 studies (23,295 participants) from 
seven of the ten Regions in Cameroon which found 
similar result with an overall HBV-HIV prevalence of 
0.8% (95% CI 0.5–1.0; 11 studies) 21whereasin rural 
Cameroon different findings have been reported: 
8.99%22, 11.8% 23 and 12.6% 24. Furthermore, 
many studies in Ghana have found the similar results of 
HIV/HBV coinfection prevalence rates 25].In fact, the 
prevalence of HIV and HBV varies geographically and 
depends on exposure to risks factors 26. 
Women were more likely to be positive for HIV and 
HIV/HBV coinfection than men. The findings are 
similar to the ones of the demographic and health 
survey carried out in Cameroon in 2011 27.  A study 
carried out in a rural village (Mfou-Cameroon) also 
highlighted a high prevalence of HIV infection and 
HIV/HBV coinfection among women 23. According 
to Cameroon’s AIDS control committee, 7 out of 10 
people living with AIDS in 2010 were women 27. For 
HBV, men were more likely to be HBV positive than 
women even if gender was not a risk factor. Previous 
studies, also found that gender was not a risk factor for 
HBV infection (p=0.953) [28, 29–30]. Diwe et al. in 
Nigeria reported that men were at higher risk of HBV 
infection than women due to needle sharing amongst 
drug addicts [31] 
 
In this study, multiple sexual partners, awareness and 
occupation were associated to both HIV and HBV 
infections. The overall high prevalence of HBV in rural 
setting as determined in this study requires the need for 
a national policy to offer HBV systematical screening 
(as done for HIV) as part of the comprehensive care for 
all patients [32].  
 
Conclusion 
This study highlighted the high prevalence of HIV and 
HBV in Ottou and its associated risk factors such as 
multiple sexual partners, awareness and 
occupation.Women seemed to be more vulnerable than 
men to HIV, whereas men were more likely to contract 
HBV. So, to achieve the 90-90-90 target, it demands 
that preventive and treatment should be carefully 
designed and implemented in communal area. 
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No*  139 17 (12.2%) 1.81 0.22-14.74 0.899 
Yes  14 1(7.14%)    
Surgery antecedent      
No   146 20(13.7%) 2.52 0.46-13.88 0.59 
Yes * 7 2(28.6%)    
Blood transfusion      
No* 143 21 (14.7%) 1.54 0.19-12.87 0.96 
Yes  10 1(10%)    
 
OR=Odds Ratio, *=Reference level of  OR ;  IC95%= intervals of  Confidence   95%  
NA=Non applicable ; n=number ;  
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